Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.

Wilson SC, Atrash B, Barlow C, Eccles S, Fischer PM, Hayes A, Kelland L, Jackson W, Jarman M, Mirza A, Moreno J, Nutley BP, Raynaud FI, Sheldrake P, Walton M, Westwood R, Whittaker S, Workman P, McDonald E.

Bioorg Med Chem. 2011 Nov 15;19(22):6949-65. doi: 10.1016/j.bmc.2011.08.051. Epub 2011 Aug 31.


Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P.

Cancer Res. 2007 Jun 15;67(12):5840-50.


Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors.

Smith NF, Hayes A, James K, Nutley BP, McDonald E, Henley A, Dymock B, Drysdale MJ, Raynaud FI, Workman P.

Mol Cancer Ther. 2006 Jun;5(6):1628-37.


Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.

Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GC, Martin NM, Workman P, Raynaud FI.

Br J Cancer. 2005 Oct 31;93(9):1011-8.


Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry.

Payne GS, Dzik-Jurasz AS, Mancini L, Nutley B, Raynaud F, Leach MO.

Cancer Chemother Pharmacol. 2005 Oct;56(4):409-14. Epub 2005 May 5.


Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.

Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, McClue SJ, Jarman M, Lane DP, Workman P.

Mol Cancer Ther. 2005 Jan;4(1):125-39.


Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.

Smith NF, Hayes A, Nutley BP, Raynaud FI, Workman P.

Cancer Chemother Pharmacol. 2004 Dec;54(6):475-86. Epub 2004 Jul 29.


Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.

Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S.

Cancer Res. 2004 Jul 15;64(14):4875-86.


Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.

O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M.

Br J Cancer. 2004 Jun 14;90(12):2317-25.


Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.

Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P.

Mol Cancer Ther. 2004 Mar;3(3):353-62.


A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.

Johnston SR, Gumbrell LA, Evans TR, Coleman RE, Smith IE, Twelves CJ, Soukop M, Rea DW, Earl HM, Howell A, Jones A, Canney P, Powles TJ, Haynes BP, Nutley B, Grimshaw R, Jarman M, Halbert GW, Brampton M, Haviland J, Dowsett M, Coombes RC; Cancer Research UK Phase I/II Committee.

Cancer Chemother Pharmacol. 2004 Apr;53(4):341-8. Epub 2004 Jan 13.


Solid-phase synthesis of novel inhibitors of farnesyl transferase.

Barber AM, Hardcastle IR, Rowlands MG, Nutley BP, Marriott JH, Jarman M.

Bioorg Med Chem Lett. 1999 Feb 22;9(4):623-6.


Inhibition of protein prenylation by metabolites of limonene.

Hardcastle IR, Rowlands MG, Barber AM, Grimshaw RM, Mohan MK, Nutley BP, Jarman M.

Biochem Pharmacol. 1999 Apr 1;57(7):801-9.


Occupational exposure to permethrin during its use as a public hygiene insecticide.

Llewellyn DM, Brazier A, Brown R, Cocker J, Evans ML, Hampton J, Nutley BP, White J.

Ann Occup Hyg. 1996 Oct;40(5):499-509.


Methylene bis (2-chloroaniline) (MbOCA): towards a biological monitoring guidance value.

Cocker J, Nutley BP, Wilson HK.

Biomarkers. 1996;1(3):185-9. doi: 10.3109/13547509609079355.


Metabolism of trans-cinnamic acid in the rat and the mouse and its variation with dose.

Nutley BP, Farmer P, Caldwell J.

Food Chem Toxicol. 1994 Oct;32(10):877-86.


A biological monitoring assessment of exposure to methylene dianiline in manufacturers and users.

Cocker J, Nutley BP, Wilson HK.

Occup Environ Med. 1994 Aug;51(8):519-22.

Supplemental Content

Loading ...
Support Center